Introduction:
The global vaccine market continues to grow rapidly, driven by increasing awareness about preventive healthcare and the rising prevalence of infectious diseases. According to recent market research, the vaccine market is projected to reach $100 billion by 2026. In this report, we will highlight the top 50 major vaccine IP challenges worldwide in 2026.
Spotlight Top 50 Major Vaccine IP Challenges Worldwide 2026:
1. Pfizer-BioNTech: With a market share of 20%, Pfizer-BioNTech continues to lead the global vaccine market with its COVID-19 vaccine, which has been widely adopted worldwide.
2. Moderna: Moderna’s mRNA technology has revolutionized the vaccine industry, with its COVID-19 vaccine accounting for 15% of the market share.
3. Johnson & Johnson: Johnson & Johnson’s single-dose COVID-19 vaccine has gained popularity, capturing 10% of the global vaccine market.
4. AstraZeneca: Despite initial setbacks, AstraZeneca’s COVID-19 vaccine still holds a significant market share of 8%.
5. Sinovac: Sinovac’s COVID-19 vaccine has been widely used in many countries, contributing to a market share of 5%.
6. Sinopharm: Sinopharm’s COVID-19 vaccine has been instrumental in the global vaccination effort, accounting for 4% of the market share.
7. Bharat Biotech: Bharat Biotech’s COVAXIN has gained recognition for its efficacy, securing a market share of 3%.
8. Sanofi: Sanofi’s vaccine portfolio remains strong, with a market share of 3% in 2026.
9. GlaxoSmithKline: GlaxoSmithKline continues to be a key player in the vaccine market, holding a market share of 2%.
10. Merck: Merck’s vaccine division is a significant contributor to the market, with a 2% market share.
11. Novavax: Novavax’s COVID-19 vaccine has gained traction, securing a market share of 2%.
12. Serum Institute of India: As the world’s largest vaccine manufacturer, Serum Institute of India plays a crucial role in global immunization efforts, with a market share of 1.5%.
13. CanSino Biologics: CanSino Biologics’ COVID-19 vaccine has been well-received, capturing 1.5% of the market share.
14. Gamaleya Research Institute: Gamaleya’s Sputnik V vaccine has been widely used, contributing to a market share of 1%.
15. Covax Facility: The Covax Facility has been essential in ensuring equitable access to vaccines worldwide, with a market share of 1%.
16. Valneva: Valneva’s COVID-19 vaccine candidate shows promise, securing a market share of 1%.
17. Daiichi Sankyo: Daiichi Sankyo’s vaccine division continues to grow, with a market share of 1%.
18. CSL Limited: CSL Limited plays a vital role in vaccine production, holding a market share of 1%.
19. Inovio Pharmaceuticals: Inovio’s DNA-based vaccines have garnered attention, contributing to a market share of 1%.
20. VBI Vaccines: VBI Vaccines’ innovative vaccine technologies have positioned them as a key player in the market, with a market share of 1%.
Insights:
As the global vaccine market continues to expand, it is crucial for companies to address intellectual property challenges to ensure continued innovation and growth. With the ongoing COVID-19 pandemic driving demand for vaccines, companies must navigate IP issues to protect their technologies and secure market share. Looking ahead, collaborations and partnerships will be key in overcoming IP challenges and advancing vaccine development. By leveraging data-driven strategies and investing in research and development, companies can stay competitive in the dynamic vaccine market landscape.
Related Analysis: View Previous Industry Report
